Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Has Average Price Target of $30.25 According to Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have earned a consensus recommendation of “Hold” from the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $30.25.

Several research firms recently weighed in on CAPR. LADENBURG THALM/SH SH cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. Piper Sandler raised shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Tuesday, September 1st. Maxim Group downgraded shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. JonesTrading cut Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 31st. Finally, Roth Capital downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target on the stock. in a research report on Monday, July 27th.

Capricor Therapeutics Stock Performance

Shares of CAPR stock opened at $6.38 on Friday. Capricor Therapeutics has a 52-week low of $2.96 and a 52-week high of $40.37. The company has a market capitalization of $370.93 million, a PE ratio of -2.60 and a beta of 0.61. The business’s fifty day moving average is $8.06 and its 200 day moving average is $20.60.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.11). On average, sell-side analysts forecast that Capricor Therapeutics will post -1.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently added to or reduced their stakes in CAPR. Activest Wealth Management lifted its stake in shares of Capricor Therapeutics by 100.0% in the third quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock worth $38,000 after buying an additional 2,000 shares in the last quarter. KBC Group NV purchased a new position in shares of Capricor Therapeutics in the first quarter worth approximately $44,000. VestGen Advisors LLC purchased a new position in Capricor Therapeutics during the third quarter valued at $191,000. SG Americas Securities LLC purchased a new stake in Capricor Therapeutics in the 1st quarter worth approximately $193,000. Finally, SBI Securities Co. Ltd. raised its position in shares of Capricor Therapeutics by 834.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 23,495 shares during the period. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.